New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:07 EDTNVSNovartis presents LBH589 data at ASCO
Novartis data at ASCO show LBH589 significantly improved progression-free survival in patients with multiple myeloma. Processed and transmitted by NASDAQ OMX Corporate Solutions. Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint. Median PFS increased by 4 months, effect of LBH589 observed across all patient subgroups. Most people with multiple myeloma will relapse or become refractory; if approved, LBH589 will be first in its class of anticancer agents available to this population. Based on these data, US FDA granted priority review in May; additional global regulatory filings are underway. The company said, "Almost all patients with multiple myeloma ultimately relapse and become resistant to treatment, so new therapies are critical for continuing to manage the disease and improve outcomes. These are the first Phase III results to show meaningful clinical benefit and provide scientific support for adding LBH589 to bortezomib-based treatment for patients with relapsed or relapsed and refractory multiple myeloma and provide a strong rationale for the use of histone deacetylase inhibitors as part of the therapeutic armamentarium in this setting."
News For NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
05:28 EDTNVSNovartis announces equity stake in Mereo BioPharma Group
Novartis announced a swap of clinical assets for equity with Mereo BioPharma Group. The deal involves compounds in areas of unmet medical need including BPS-804, to improve bone density in brittle bone syndrome, an orphan disease; BCT-197 for acute exacerbations in COPD, and BGS-649 for obese men with hypogonadotrophic hypogonadism to normalize testosterone levels. Under the terms of the agreement, Novartis will have an equity stake in Mereo and will share in the success of the development of these compounds, including a share on milestones and royalties on future commercial sales.
July 24, 2015
10:56 EDTNVSNovartis announces FDA approval of Odomzo
Subscribe for More Information
09:02 EDTNVSLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information
07:17 EDTNVSNovartis combination therapy Tafinlar, Mekinist achieves regulatory milestones
Subscribe for More Information
July 22, 2015
07:03 EDTNVSIgnyta names Bernard Parker as Chief Commercial Officer
Subscribe for More Information
July 21, 2015
11:49 EDTNVSNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
05:20 EDTNVSNovartis backs FY15 revenue guidance of up mid-single digit
Subscribe for More Information
05:17 EDTNVSNovartis reports Q2 core EPS $1.27, consensus $1.24
Reports Q2 revenue $12.7B, consensus $12.44B. Further strengthening of USD impacted sales by -11% and core operating income by -13%. Growth Products, an indicator of the rejuvenation of the portfolio, contributed 35% of continuing operations net sales in Q2, and were up 24%. In Pharmaceuticals, Growth Products contributed 44% of division net sales in the quarter, and sales for these products were up 38%.
July 20, 2015
08:25 EDTNVSNovartis management to meet with JPMorgan
Subscribe for More Information
07:32 EDTNVSAlzheimer's Association to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use